Sodium-glucose cotransporter 2 (SGLT-2) inhibitors have shown cardiorenal benefits in the general population; however, evidence regarding their efficacy and safety in kidney transplant recipients (KTRs) remains sparse. This evidence concerns the gene SLC5A2 and kidney transplant.